Q2 2026 Alexandria Real Estate Equities, Inc Earnings Call Transcript
Key Points
- Leasing volume for Q2 2026 was solid at 1,039,000 square feet, up 60% quarter-over-quarter and 9% above the historical average.
- Strong leasing from life science tools and advanced technology sectors, with advanced tech tenants providing lower CapEx and faster lease-up opportunities.
- Continued occupancy outperformance of 8% to 12% across the three largest markets compared to broader market averages.
- Completed a 427,000 square foot build-to-suit for Bristol-Myers Squibb, adding significant NOI and long-term value.
- Extended the $5 billion credit facility to 2032, ensuring strong liquidity and financial flexibility.
- Progress on capital plan with 46% of the $2.9 billion target completed or pending, and no common equity issuance assumed for 2026.
- G&A expense savings of $76 million combined for 2025-2026, with G&A as a percentage of NOI at 6.6%, well below the S&P 500 REIT average.
- Tenant demand is improving, with a 10% quarter-over-quarter increase in tenants in the market, particularly in the 20,000-100,000 square foot range.
- Leased 1.4 million square feet expected to commence by November 2026, generating $69 million in annual rental revenue.
- Strong balance sheet with the longest average debt maturity among S&P 500 REITs at 9.7 years.
- Occupancy declined 80 basis points to 86.9% in Q2 2026, driven by known lease expirations and reclassification of a building.
- Same-property NOI decreased 10.6% on a GAAP basis and 8.6% on a cash basis, though improved from the prior quarter.
- Leasing of development/redevelopment pipeline remains slow, with only 70,000 square feet leased in Q2.
- 2027 key lease expirations of 1.4 million square feet are expected to have 12-24 months of downtime, impacting future revenue.
- Disposition timing has slipped, with the weighted average completion now expected in September, and some transactions are taking longer due to financing challenges.
- Recognized $222.5 million in impairments during the quarter, primarily related to land and lab conversion opportunities.
- Leverage remains elevated at 7.0x net debt to annualized adjusted EBITDA, though expected to decline to 5.6-6.2x by year-end.
- Capitalized interest guidance was reduced by $5 million due to earlier project completions, impacting Q4 FFO.
- Public biotech leasing remains weak, accounting for only 5.8% of Q2 leasing volume, below its 21% share of annual rents.
- Potential additional impairments may be recognized in coming quarters as assets are evaluated for sale.
Good afternoon, everyone, and welcome to the Alexandria Real Estate Equities second quarter 2026 conference call. (Operator Instructions) Please also note, today's event is being recorded. At this time, I'd like to turn the floor over to Paula Schwartz with Investor Relations. Please go ahead.
Thank you, and good afternoon, everyone. This conference call contains forward-looking statements within the meaning of the federal securities laws. The company's actual results might differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained in the company's periodic reports filed with the Securities and Exchange Commission.
And now I'd like to turn the call over to Joel Marcus, Executive Chairman and Founder. Please go ahead, Joel.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
